Applied Clinical Trials-09-01-2019

Applied Clinical Trials
Feature Articles

September 01, 2019

Executives from across the clinical research enterprise converge to discuss the steps-and technology-needed to strengthen industrywide data sharing.

Applied Clinical Trials

Joel B. Selzer, co-founder and CEO, ArcheMedX, Inc., discusses the impact that healthcare technology has on clinical trials, focusing on the development of the company’s workforce readiness platform.

Applied Clinical Trials
Feature Articles

September 01, 2019

Exploring how clinical research sites are redefining their business models to be more flexible, collaborative, and customized.

Applied Clinical Trials
Feature Articles

September 01, 2019

After years of siloed focus-and slow study start-ups-the U.S. Veterans Affairs agency embarks on implementing its multi-year initiative to bolster clinical research.

The two-year inquiry into possible maladministration at the EMA has intensified.

Issue PDF
Applied Clinical Trials

September 01, 2019

Click the title above to open the Applied Clinical Trials September 2019 issue in an interactive PDF format.

FDA and other regulators are responding with support for more flexible monitoring of clinical investigators and review of study records in order to limit study monitoring to certain situations.

Applied Clinical Trials
Feature Articles

September 01, 2019

Bristol-Myers Squibb’s cardiovascular development leader discusses the importance of diversifying clinical trials for better patient outcomes.

Applied Clinical Trials
From the Editor

September 01, 2019

A view of highlights and trends from the September 2019 issue, alongside trends mentioned around site practices during the year.

Applied Clinical Trials

Interest in benchmark data on the scope, performance, and economics of rare disease drug development efforts has grown.

Applied Clinical Trials

A case study of the Parkinson’s Progression Markers Initiative.

Applied Clinical Trials

Organizations that continue to disregard the technological needs of one of the industry’s core audiences run the risk of having their trials ignored.